Market news

RXRX's strategic partnerships are expanding its drug pipeline, strengthening AI capabilities and providing non-dilutive funding through early 2028.

The latest trading day saw Recursion Pharmaceuticals (RXRX) settling at $4.05, representing a +2.02% change from its previous close.

Recursion Pharmaceuticals (RXRX) is back on traders’ screens after a sharp daily move, with the share price closing at US$3.83. Recent returns have been mixed over the past week and month. For context, Recursion Pharmaceuticals has delivered an 8.19% 1-day share price return and a 19.69% 7-day share price return, yet the total shareholder return over the past year is down 22%. This hints at short-term momentum building against a more difficult long-term backdrop and shifting views on the...

In the latest trading session, Recursion Pharmaceuticals (RXRX) closed at $3.18, marking a -1.85% move from the previous day.

AI is reshaping drug discovery, with Recursion Pharmaceuticals, Schrodinger, Relay Therapeutics and Absci advancing computational platforms and pipelines.

In the most recent trading session, Recursion Pharmaceuticals (RXRX) closed at $3.34, indicating a +1.21% shift from the previous trading day.

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) is one of the Best Penny Stocks to Invest In According to Billionaires. Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) is a biotechnology company that is building an AI-native discovery platform to industrialize drug discovery. Although still in the clinical stage, the company generates much of its revenue from key partnerships and collaborations with […]

In late June 2026, Recursion Pharmaceuticals, Inc. was added to multiple Russell value and small-cap benchmarks, including the Russell 2000 Value Index, expanding its presence in key equity indices. This index inclusion comes as Recursion’s AI‑native drug discovery platform and recent clinical and data‑driven milestones increasingly draw interest from large investors and collaborators. We’ll now examine how this broader index inclusion, alongside Recursion’s AI‑driven discovery progress,...